Neuroendocrine Tumour Screen

Clinical Use: Diagnosis and subsequent monitoring of a diverse group of neoplasms that arise from the endocrine and nervous systems. The large number of potential serum tumour markers associated with tumours of this type necessitates a panel of markers being assembled resulting in the screens listed below. Patient symptoms may aid the clinician in selecting the appropriate screen.
Background: Neuroendocrine Tumour Screen (NET2) – This is an appropriate screen for mid gut carcinoids and when the location of the primary tumour is unknown. It is also suitable for primary pancreatic tumours.
Tests will be done in two groups:
Group 1 – Chromogranin A, Neurokinin A, Gastrin and Pancreatic Polypeptide
Group 2 – Pancreastatin, Somatostatin, Glucagon, Vasoactive Intestinal Peptide and Insulin.
Reference Ranges: Please see report
Associated Diseases:
Patient Preparation: For suspected gastrinomas, patient off proton pump inhibitors for 2 to 3 days, then request Gastrin, Chromogranin A and Pancreatic Polypeptide.
Specimen Requirements: 3 x EDTA tubes
Turnaround Time: 4 weeks
Additional Information:
Referred Test: Referred test
Location: SAS laboratory